Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Primary Ciliary Dyskinesia
Interventions
DIETARY_SUPPLEMENT

Glycine

Patients will receive for 6 months an oral supplement of 0.5 g/kg/day glycine, up to 25 g/day, divided in three daily intakes.

DIETARY_SUPPLEMENT

Magnesium+thiamine

Patients will receive for 6 months an oral supplement of up to 400 mg/day, according to age, of elementary magnesium (formulated as magnesium citrate) plus up to 10 mg/day of thiamine (formulated as benfotiamine), divided in three daily intakes.

OTHER

Placebo

Patients will receive for 6 months placebo (sugar glass), in a similar daily amount as in experimental arms, and divided in three daily intakes.

Trial Locations (1)

14080

Instituto Nacional de Enfermedades Respiratorias, Mexico City

All Listed Sponsors
lead

Instituto Nacional de Enfermedades Respiratorias

OTHER_GOV

NCT06959251 - Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia | Biotech Hunter | Biotech Hunter